SV7 Impact Medicine Fund LP's Form 4/A amendment
AmendedXilio Therapeutics, Inc.XLO · filed Nov 3, 2021
- Accession no.
- 0000899243-21-042710
- Filed
- Nov 3, 2021, 4:20 PM ET
- Trade date
- Oct 26, 2021
- Filing delay
- 8 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Oct 28, 2021
This filing lists 6 non-derivative transactions and 4 derivative transactions. Open-market purchases total $10.0M. It was filed 8 days after the trade.
This amendment replaces 0000899243-21-041838 (filed Oct 28, 2021).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| SV7 Impact Medicine Fund LPCIK 0001780602 | 10% Owner |
| SV7 (Imf) GP LLPCIK 0001889859 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 26, 2021 | Common Stock | CConversionAcquired | +998,544 | –F1 | – | 998,544 | Direct | |
| Oct 26, 2021 | Common Stock | CConversionAcquired | +998,544 | –F1 | – | 998,544 | Indirect | |
| Oct 26, 2021 | Common Stock | CConversionAcquired | +302,588 | –F1 | – | 1,301,132 | Direct | |
| Oct 26, 2021 | Common Stock | CConversionAcquired | +302,588 | –F1 | – | 1,301,132 | Indirect | |
| Oct 26, 2021 | Common Stock | PPurchaseAcquired | +312,500 | $16.00 | +$5,000,000 | 1,613,632 | Direct | |
| Oct 26, 2021 | Common Stock | PPurchaseAcquired | +312,500 | $16.00 | +$5,000,000 | 1,613,632 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 26, 2021 | Common Stock | CConversionDisposed | −998,544 | $0.00 | $0 | 0 | Direct | |
| Oct 26, 2021 | Common Stock | CConversionDisposed | −998,544 | $0.00 | $0 | 0 | Indirect | |
| Oct 26, 2021 | Common Stock | CConversionDisposed | −302,588 | $0.00 | $0 | 0 | Direct | |
| Oct 26, 2021 | Common Stock | CConversionDisposed | −302,588 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date.
Referenced by the price of 4 transactions in Table I.
- F2
Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021.
- F3
Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom.
- F4
This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering.